No Data
Guobang Pharmaceuticals (605507): From Scale to Growth
Investment key sentence logic: Large-tonnage active pharmaceutical ingredient companies reflecting scale advantages, the recovery of the animal health business is expected to drive performance beyond expectations. Fundamental: Pharmaceuticals stabilize growth, animal health expected to recover. 1. Pharmaceutical business: Volume and price rises, expansion expected. The company's large cyclic internal esters.
Guobang Pharmaceutical (605507.SH): Zhejiang Min Investment Henghua, Silk Road Fund have cumulatively reduced their shareholding by 2.56%.
Country Health Pharmaceuticals (605507.SH) announced on November 29th that the company received a Notice of Shareholding Reduction Results from Zhejiang Civilian Investment Henghua and Silk Road Fund on November 29, 2024. As of November 29, 2024, Zhejiang Civilian Investment Henghua and Silk Road Fund collectively reduced the company's shares by 14,303,883 shares, accounting for 2.56% of the total share capital of the company. The shareholding reduction plan has been completed.
Pacific Securities: Q3 revenue and profit growth of the active pharmaceutical ingredient sector have accelerated significantly, bullish on the high growth trend in Q4 performance.
In Q1 2024, the sector's gross margin is 36.38%, with a net margin of 12.78%. Q2 gross margin is 37.21%, with a net margin of 15.52%. Q3 gross margin is 38.27%, +1.88pct year-on-year, +1.06pct quarter-on-quarter, and net margin is 14.07%, +3.98pct year-on-year, -1.45pct quarter-on-quarter. Both gross margin and net margin have reached a new high compared to the same period in the past three years.
Guobang Pharmaceutical (605507.SH): has repurchased 1.11% of the shares accumulated.
Grain de Glory on November 1st | Guobang Pharmaceutical (605507.SH) announced that as of October 31, 2024, the company had repurchased a total of 6,212,400 shares through centralized auction trading, with the repurchased shares accounting for 1.11% of the total share capital of the company. The highest price traded was 18.66 yuan/share, the lowest price was 13.05 yuan/share, and the total amount paid was 100,995,168.00 yuan (excluding transaction costs).
Guobang Pharmaceutical (605507): Q3 revenue hits a record high, foreign exchange gains and losses have a short-term impact on profit levels.
On October 18, 2024, the company released the third quarter report of 2024, with revenue of 4.418 billion yuan in 2024Q1-3 (+9.00% YoY) and a net income attributable to the parent company of 0.579 billion yuan.
Guobang Pharma's Q3 Profit Rises 32%
No Data
No Data